Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
髿é·
å瀟ã®åçã¯éå»3幎éã«ãããçå®ã«å¢å ããŠããã幎平åã§62.73%ã®æé·çã瀺ããŠããŸãã
æé·äž
åç€Ÿã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 14.56Mã«éããŠããŸãã
é«ãå©çæé·
å瀟ã®çŽå©çã¯æ¥çããªãŒãããŠãããææ°ã®å¹ŽéçŽå©çã¯USD 14.56Mã§ãã
å²é«
åç€Ÿã®ææ°ã®PEã¯-4.87ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé«å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯114.20Mæ ªã§ãåååææ¯ã§5.62%æžå°ããŠããŸãã
ã¹ãã£ãŒãã³ã»ã³ãŒãšã³ãä¿æ
ã¹ã¿ãŒæè³å®¶ã¹ãã£ãŒãã³ã»ã³ãŒãšã³ã¯æ¬éæã369.92Kæ ªä¿æããŠããŸãã
åžå ޿޻åãæŽ»çº
å瀟ãžã®æè³å®¶ã®é¢å¿ãé«ãŸã£ãŠããã20æ¥éã®å£²è²·å転çã¯0.30ã§ãã